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 The purpose of these studies was to explore the roles of dietary strategies and bariatric 
surgery in obesity treatment. The breakfast study was a randomized, crossover trial used to 
evaluate the role of egg proteins, and a retrospective chart review was conducted to obtain 
comparative information about two different bariatric surgeries.  
The breakfast study included 20 subjects who were randomized to receive an egg 
breakfast (EB) or a cereal breakfast (CB) matched for energy density and macronutrient 
composition but different protein quality for one week. Following a washout period, each subject 
was crossed over to receive the opposite breakfast for one week. The EB resulted in lower 
cumulative lunchtime food intake (p=0.05), reduced hunger on day 1 (p=0.001), greater feelings 
of fullness on days 1 and 7 (p=0.02), and decreased desire to eat on day 1 (p=0.03). Acylated 
ghrelin was lower on day 1 of the EB compared to the CB (p=0.005) but not on day 7. PYY was 
greater at 120 minutes (p=0.006) and 180 minutes (p=0.001) on day 1 and at 180 minutes on day 
7 (p=0.03) after the EB.    
 The bariatric surgery studies examined 835 Roux-en-Y gastric bypass (RYGB) patients 
and 766 vertical sleeve gastrectomy (VSG) patients. Study one focused on patients diagnosed 
with type 2 diabetes (T2D). The acute effect bariatric surgery had on resolving T2D was 
measured by calculating the number of patients who discontinued their hypoglycemic medication 
use post-operatively. Upon discharge, 95 of the 123 (77.2%) RYGB patients and 107 of the 139 
(77.0%) VSG patients had been taken off their medication. Eight weeks post-operatively, 30 of 
the 38 (~79%) RYGB patients and 59 of the 71 (83%) VSG patients with follow-up data 
remained off medication. Study two examined differences in weight loss, early post-operative 
surgical complications, and insurance coverage between RYGB and VSG patients. RYGB 
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patients lost more weight at one and two years (p<0.001 for both). There was no significant 
difference in the percentage of weight loss or complications in insured versus self-pay patients. 








When energy intake exceeds energy expenditure, the positive energy balance leads to the 
storage of excess energy as fat1. The abundance of food in the current environment combined 
with increasingly sedentary lifestyles contributes to positive energy balance1. Genetics also play 
a role in body fat regulation1. The genetic makeup of modern man has not significantly changed 
since the era of the hunter-gather society1, 2.  During that time, humans ate copiously when food 
was abundant and were able to store excess energy as fat for times when food was unavailable1. 
This genetic predisposition to store fat combined with behavioral and environmental factors may 
explain why many individuals are growing obese.     
Obesity, a disease of excess energy stored as adipose1, 3, has become an epidemic in the 
US 4, 5. Approximately 1/3 of the adult population is considered obese6. The World Health 
Organization (WHO) divides obese individuals into three classes: class I (BMI = 30-34.9 kg/m2), 
class II (BMI = 35.0-39.9 kg/m2), and class III (BMI > 40 kg/m2)7, 8. Individuals within class III 
are morbidly obese which indicates they are at least 100 pounds overweight3. If current obesity 
trends continue, data from the National Health and Nutrition Examination Study (NHANES) 
project that 51.1% of all adults in the US will be obese by 20305, and global projections surpass 
one billion people by 20309. 
Not only is obesity linked to a harsh social stigma10, but it is also linked to many co-
morbid conditions such as cardiovascular disease11, 12, hypertension11-13, diabetes11, 12, obstructive 
sleep apnea11-13, certain cancers12, and degenerative joint disease3, 12, 13. According to one 
prospective study of over 4500 obese patients, the most common co-morbidities were 
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hypertension (55.1%), obstructive sleep apnea (48.9%), diabetes (33.2%), and asthma (23.1%)14.  
More than 50% of these patients had at least two co-morbid conditions14. Even without any 
existing co-morbid conditions, obesity increases the risk of mortality15. In 2000, approximately 
360,000 deaths were obesity-related11.  Because obesity increases the risk of other diseases, 
healthcare costs for obese individuals exceed those of normal weight individuals16. In 2008, 
obesity-associated medical costs were estimated to be $147 billion dollars16 and are projected to 
reach $960 billion dollars in the next two decades5. 
The World Health Organization (WHO) and National Institutes of Health (NIH) clinical 
guidelines for obesity suggest obese individuals should reduce their energy intake and increase 
their energy expenditure to induce a 10% weight loss17, 18. Diets of different macronutrient 
compositions have been found to result in similar weight loss of 7% after 6 months19, and a diet 
that follows a 25% caloric restriction has been shown to result in a 10% weight loss at 24 
weeks20. Dietary strategies that decrease hunger and increase satiety may be useful for 
individuals following a reduced-energy diet. Holt et al21 tested the effect of several foods on their 
ability to induce satiety and found that eggs have twice as much satiety-inducing capability as 
ready-to-eat breakfast cereals22. Eating a daily breakfast, especially one that is high in protein, 
has been shown to reduce ghrelin23, increase peptide YY24, and reduce energy intake for the 
remainder of the day25. Thus, eating high-protein foods such as eggs for breakfast may enhance 
weight loss.  
Engaging in physical activity can increase energy expenditure and lead to a reduction in 
weight and body fat26. Exercise also plays a role in the prevention of weight gain26. 
Pharmacologic agents such as orlistat can be used in combination with lifestyle modifications to 
augment weight loss and aid in weight loss maintenance27. However, of all the obesity treatment 
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alternatives available, bariatric surgery is the most effective treatment for morbid obesity8, 28. 
Numerous studies have found that clinically significant weight loss can be achieved through 
bariatric surgery within one to two years and can be maintained over time29. If attempts to lose 
weight through diet, exercise, and obesity drugs fail, individuals may seek bariatric surgery to 
lose weight and to improve or resolve any co-morbidities. 
Justification  
 Because obesity currently affects 1/3 of the US adult population, and the number of obese 
adolescents and children is also increasing, obesity treatment alternatives need to be examined 
for their effectiveness in inducing and maintaining weight loss. Dietary approaches to obesity 
may be the safest method for weight management, but few studies show diets that result in 
significant maintenance of weight loss. Dietary strategies for weight loss that individuals can 
easily follow over time are needed. Bariatric surgery appears to result in significant weight loss, 
but most studies focus on the more established gastric bypass. Few studies examine large 
samples of a newer bariatric operation, the vertical sleeve gastrectomy.      
Research Questions 
1. Does protein quality affect food intake and satiety in overweight adults?  
2. Does the vertical sleeve gastrectomy resolve diabetes as effectively as the Roux-en-Y 
gastric bypass?  
3. Does the vertical sleeve gastrectomy result in similar weight loss to the Roux-en-Y 
gastric bypass?  
4. Does the vertical sleeve gastrectomy result in fewer or greater complications than the 
Roux-en-Y gastric bypass?  
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5. Does payment method (i.e. insurance or self-pay) influence weight loss in vertical sleeve 
gastrectomy patients and Roux-en-Y gastric bypass patients?  
Objectives 
1. To determine if consuming a breakfast with high quality protein is associated with 
increased satiety and decreased food and energy intake at lunch.  
2. To determine if the vertical sleeve gastrectomy is as effective as the Roux-en-Y gastric 
bypass in resolving diabetes.  
3. To determine if the vertical sleeve gastrectomy results in similar weight loss with a 
similar or lower complication rate than the Roux-en-Y gastric bypass and if insurance 
reimbursement affects weight loss.     
 
Hypothesis  
1. A breakfast containing greater protein quality will decrease food intake and increase 
satiety in overweight adults more than a breakfast with lower protein quality.  
Limitations  
1. The breakfast study did not measure GLP-1 following breakfast or lunch. 
2. The breakfast study had a small sample size (n=20).  
3. The breakfast study only showed an acute effect of each breakfast.  
4. The bariatric surgery studies were based upon information from a retrospective chart 
review. 
5. The bariatric charts had limited follow up so long-term results were not obtained.  
6. The bariatric charts lacked laboratory data to show changes in glucose, insulin, 




1. The information contained in the bariatric charts was accurate and reliable.  
Definitions  
1. National Health and Nutrition Examination Survey (NHANES): a continuous program 
that collects information about the nutrition and health status of the US population using 
a complex, multi-stage probability sampling design 
2. Body Mass Index (BMI): body weight (kg) divided by height (m2) used as a measurement 
to classify weight status 
3. Obesity: BMI > 30 kg/m2 
4. Morbid obesity: BMI > 40 kg/m2  
5. Satiety index score (SIS): score that measures a food’s satiating capabilities   
6. Branched chain amino acid (BCAA): amino acids with an aliphatic side chain; include 
the amino acids leucine, isoleucine, and valine  
7. Jejuno-ileal bypass (JIB): one of the first bariatric procedures used to induce weight loss 
but was discontinued because it resulted in severe complications  
8. Roux-en-Y gastric bypass (RYGB): a bariatric procedure involving the creation of a 
small gastric pouch combined with a gastrointestinal bypass which excludes the 
duodenum and the proximal jejunum 
9. Vertical sleeve gastrectomy (VSG): a bariatric procedure involving a subtotal gastric 
resection of the fundus and body to create a long, tubular gastric conduit along the lesser 
curve of the stomach  
10. National Institutes of Health (NIH): the medical research agency of the United States 
11. World Health Organization (WHO): the authority for health within the United Nations 
system which manages global health issues and the health research agenda  
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12. Excess weight: mid-point in the range of ideal body weight as defined by the 1983 
Metropolitan Life Insurance Tables for a medium frame subtracted from initial weight  
13. Excess weight loss (EWL): [Weight loss (lbs)/Excess weight (lbs)]*100 
14. Type 2 diabetes (T2D): chronic disease in which blood glucose levels are elevated as a 
result of insulin resistance with or without a defect in insulin secretion by the pancreatic 
beta cells   
15. Homeostatic Model Assessment (HOMA): model used to quantify insulin resistance and 
beta-cell function  
16. American Society for Metabolic and Bariatric Surgery (ASMBS): society created to 
advance the science of bariatric surgery whose goal is to improve the treatment of obesity 
and obesity-related diseases through the understanding of metabolic surgery  
17. Glucagon-like peptide 1 (GLP-1): peptide hormone produced by the L cells which is 
released in response to meal intake and may act as physiological regulator of food intake 
by suppressing appetite after the consumption of food 
18. Peptide YY (PYY): peptide hormone produced by the L cells which is released in 
response to meal intake and may act as physiological regulator of food intake by 
suppressing appetite after the consumption of food 
19. Acylated ghrelin: orexigenic hormone secreted primarily in the stomach which plays a 








REVIEW OF LITERATURE  
 Obesity has become a nationwide epidemic over the past few decades5, 13, 30, 31. No state 
had a prevalence of obesity greater than 15% in 1990, but only two decades later in 2010, no 
state had a prevalence less than 20%30. Currently, 36 states have an obesity prevalence greater 
than or equal to 25%30. The morbidly obese population doubled between 2000 and 200511, and 
data from the 2007-2008 National Health and Nutrition Examination Survey (NHANES) has 
shown that 33.8% of the United States (US) adult population is obese32. 
 Weight is affected by a combination of genetic, behavioral, and environmental factors33. 
Behavioral factors include diet composition and exercise, and environmental factors include 
where a person lives, works, and socializes33. Although genetics do play a role in some obesity-
related diseases, the human genome has not changed enough to completely explain the rise in 
obesity33. The “thrifty gene” hypothesis states that the body’s process of storing calories as fat 
during abundance in the days of early humans may now be working to our disadvantage34. Food 
is now readily available, and current lifestyles are more sedentary and less labor-intensive 
compared to the hunter-gatherer era2. In addition, when the amount of adipose tissues changes, 
the body’s desire to maintain energy homeostasis resists weight change31. Thus, the lifestyle 
followed by many individuals leads to a positive energy balance in which more calories are 
consumed than expended on a daily basis.  
Because obesity increases the risk of co-morbidities and mortality, effective strategies 
should be utilized to induce weight loss. Currently, obesity treatment options include diet, 
exercise, behavioral modification, anorectic drugs, and bariatric surgery27, 35. Non-surgical 
approaches to obesity typically result in minimal weight loss, and over long periods of time, may 
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result in weight regain15, 28. However, many individuals attempt to lose weight through diet and 
exercise26, 36 before undergoing more drastic measures such as bariatric surgery. Also, 
individuals must be morbidly obese to be clinically eligible to undergo bariatric surgery. A study 
that examined weight loss diets in over 800 subjects showed that all the diets produced an 
average weight loss of four kilograms after two years regardless of macronutrient composition19. 
Thus, calorie restriction appears to be the most important factor for dieting and not macronutrient 
composition19, 27. A study examining the chronic effect of caloric restriction showed that a diet 
that restricted normal caloric intake by 25% resulted in ~10% weight loss at 24 weeks20. 
However, adherence to a low kilocalorie diet can be difficult to maintain over time so using 
dietary strategies that decrease hunger and increase satiety may improve weight loss efforts37, 38.  
One easily adaptable strategy that may improve weight loss efforts is to eat a daily 
breakfast39. Body mass index (BMI) and breakfast consumption are negatively correlated40. 
Although breakfast eaters have been shown to have a higher daily energy intake, they have been 
shown to have lower BMIs than breakfast skippers40-42. Because breakfasts differing in 
macronutrient composition have not been shown to affect lunchtime energy intake differently43, 
individuals should consider consuming breakfast foods known to increase satiety. Eggs, a 
common breakfast food, have been found to have a 50% greater satiety index scores (SIS) than 
ready-to-eat cereal21. Eggs have been shown to increase satiety and decrease lunchtime energy 
intake22. When individuals ate eggs daily for breakfast in addition to following a reduced calorie 
diet, they reduced their BMI and waist circumference more than individuals who ate an 
isocaloric bagel breakfast37. They also displayed greater dietary restraint and had greater 
reductions in hunger than bagel breakfast eaters37. In contrast, cross-sectional data from 
NHANES has shown that individuals who consume ready-to-eat cereals have lower BMIs than 
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meat and egg breakfast eaters40. However, these results may indicate that eating eggs can be a 
marker of other dietary indiscretions. Thus, including eggs as part of a daily breakfast may 
induce greater results in a weight loss regimen. 
High-protein diets appear to result in greater reductions in weight because protein 
increases satiety and thermogenesis, reduces loss of lean body mass, and promotes body fat loss, 
and improves glycemic control44. Individuals who increased their protein intake at breakfast had 
decreased postprandial ghrelin concentrations23 and thus decreased hunger23, 45.  Increased intake 
of protein, especially higher quality proteins, has been shown to enhance weight loss44, 46, 47. 
Consuming more protein also leads to an increased intake of the branched chain amino acid 
(BCAA) leucine46. The satiating effect of eggs may possibly be due to the high quality of egg 
proteins which are rich in leucine and has been implicated in inducing satiety44, 47, 48. Leucine 
promotes protein synthesis and regulates insulin release and signaling49. A study by Layman et 
al
46 compared a moderate protein diet and a high carbohydrate diet with different amounts of 
leucine (9.89±0.19 g and 5.39±0.10 g, respectively) over a 10-week period. Subjects in the 
protein group lost more weight and body fat but less lean body mass than the carbohydrate group 
although the differences were not significant46. However, this suggests that leucine acts as a 
metabolic regulator, and through its actions in insulin and glucose, can preserve lean muscle 
while reducing body fat.  
Several drugs have been developed to treat obesity through weight reduction50. Orlistat 
prevents ~30% of fat absorption when taken with a meal27, but it only produces an average 
weight loss of 2.9 kg at 12 months27, 50. Anti-obesity drugs such as rimonabant and sibutramine 
produced a weight loss between 3-5 kilograms in six months to one year, but they have been 
withdrawn from the market due to adverse side effects27, 50. Because few anorectic drugs are 
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available on the market, and many people struggle to lose a clinically significant amount of 
weight through diet and exercise, they may elect to undergo bariatric surgery.    
The first bariatric operation, the jejuno-ileal bypass (JIB), was performed in 1954; 
however, it resulted in severe complications including hepatic and renal failure51. Several years 
later, Dr. Edward Mason’s observations led to the development of the gastric bypass, an 
operation that resulted in significant weight loss but less severe complications than the JIB52. In 
1994, Wittgrove and Clark introduced the laparoscopic technique for the gastric bypass which 
has been shown to have certain advantages over the previously used open method28, 51. Surgeons 
conduct a Roux-en-Y gastric bypass (RYGB) by first creating a small gastric pouch 20-30 
milliliters in volume. The duodenum and proximal jejunum are bypassed, and a Roux limb 75-
105 centimeters long reroutes the distal jejunum and ileum to the pouch11. The RYGB is a 
restrictive and malabsorptive procedure that induces weight loss through a combination of food 
restriction and malabsorption51. 
The vertical sleeve gastrectomy (VSG), a much newer bariatric operation, was originally 
the first step in the biliopancreatic diversion with duodenal switch13, 53, 54. To decrease the risk of 
surgical complications and mortality in super obese individuals, individuals would first undergo 
the sleeve gastrectomy which was later followed by a second step13, 55. However, the weight loss 
and co-morbidity resolution achieved with the VSG alone has prompted the use of the VSG as a 
primary procedure13, 55. The sleeve gastrectomy entails a resection of the greater curvature of the 
stomach which creates a tubular stomach and preserves the pylorus and part of the antrum11.   
The VSG is a restrictive procedure that induces weight loss through the restriction of food 
intake51. Because part of the stomach is removed, gut hormones are also affected and may be a 
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potential mechanism aiding in weight loss56. Currently, the VSG accounts for less than 5% of all 
bariatric procedures in the US53, 57. 
The number of bariatric operations performed annually increased 900% between 1998 
and 200458. In spite of this significant increase, only 1% of clinically eligible patients undergo a 
bariatric operation each year11. According to criteria established by the National Institutes of 
Health (NIH), an individual must be morbidly obese (BMI > 40 kg/m2) or have a BMI > 35 
kg/m2 with a serious co-morbid condition such as cardiopulmonary disease or diabetes to be 
eligible for a bariatric operation35. Today, the laparoscopic gastric bypass comprises the majority 
of bariatric operations in the US14, 59. 
Bariatric surgery appeals to morbidly obese individuals because it has been shown to 
result in clinically significant, sustainable weight loss. The average BMI for individuals electing 
to have bariatric surgery is greater than 40 kg/m2 60-62. The RYGB has been shown to result in an 
average excess weight loss (EWL) of 50.2±6.5% at six months post-operatively56, and has 
reached ~70% at one year56, 62. One long-term study showed that RYGB patients can maintain an 
EWL of 49% 14 years post-operatively29. Similarly, the VSG has resulted in an average excess 
weight loss ranging from ~39% to ~56% at six months56, 63, 49% to ~70% at one year56, 62, 63, and 
~68% at two years post-operatively64. Average excess BMI loss one year post-operatively for the 
RYGB and VSG is 70.1% and 55.3%, respectively65. Currently, limited data exists in the 
literature describing long-term weight loss produced by the VSG66.    
Bariatric surgery also has also been shown to improve or resolve co-morbid conditions 
such as diabetes significantly more than non-surgical options67, 68. Several studies comparing the 
RYGB and VSG demonstrated that both surgeries comparably resolve hypertension, 
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dyslipidemia, obstructive sleep apnea, and type 2 diabetes (T2D)69. One prospective study that 
followed 608 morbidly obese patients for 14 years after gastric bypass surgery showed surgery is 
the most effective treatment for maintaining normal plasma glucose concentrations in individuals 
with T2D or impaired glucose tolerance29. Although diabetic medications help control blood 
glucose levels, they may not prevent the progression of the disease which leads to microvascular 
complications including retinopathy, nephropathy, and neuropathy. T2D may also lead to 
cardiovascular disease which accounts for 70% of the deaths in individuals with T2D in the 
US68.  
The VSG has similar efficacy to the RYGB in T2D remission70, 71. The RYGB and VSG 
resolved T2D in approximately 85% of subjects (n=91) in one study at one year post-
operatively70, and a study comparing the VSG and RYGB in 90 patients found no significant 
differences in diabetes control between the two operations at one and two years71. Both surgeries 
appear to result in early, dramatic improvements in glycemic control and Homeostatic Model 
Assessment (HOMA) indices that are maintained post-operatively72. However, conflicting ideas 
remain on the efficacy of the VSG because the proximal small intestines are not excluded72, 73. 
Lee et al demonstrated greater T2D resolution in RYGB patients compared to VSG patients at 12 
months (93% and 47%, respectively) which they attributed to the exclusion of the duodenum73. 
In contrast, Nocca et al found that more VSG patients discontinued taking diabetic medication 
than RYGB patients74. Bariatric surgery can also effectively improve or resolve many other 
conditions in the majority of patients55, 61, 69, 75, 76, and it can also decrease the risk of mortality by 
35% compared to morbidly obese individuals who do not undergo obesity surgery14, 15.  
Studies have shown low overall mortality rates following bariatric surgery ranging from 
0.1% to 1.5%57, 59, 77.  Thirty-day mortality rates appeared to be less than 0.2% for all bariatric 
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operations57, 59, and less than 2% specifically for RYGB78. The mortality rate for VSG patients 
appears to be less than 1%12, 13, 79. According to data of over 66,000 surgeries from the American 
Society for Metabolic and Bariatric Surgery (ASMBS) Centers of Excellence, the three 
predominant causes of mortality were pulmonary emboli, cardiac complications, and 
sepsis/infection59. 
Common minor complications identified by the ASMBS include atelectasis, dehydration, 
diarrhea, dumping syndrome, esophageal reflux, pneumonia, nausea and vomiting, and 
infection80, 81. Common major complications include cardiopulmonary issues such as cardiac 
arrest, deep venous thrombosis, pulmonary embolism and respiratory arrest or failure, 
gastrointestinal (GI) bleeds or leaks, small bowel obstruction, anastomotic stricture, ulcer at the 
anastomosis or in the GI tract, and wound dehiscence or infection80, 81. Complications 
experienced by patients appear to be dependent on the type of surgery and the surgeon’s 
experience78. A review of 3,464 gastric bypass cases found wound infections, anastomotic leaks, 
gastrointestinal tract hemorrhages, bowel obstructions, and pulmonary emboli were the most 
common complications occurring in the early post-operative period82. Studies report differing 
overall total complication rates in RYGB patients. Sjostrom et al83 and Carrodeguas et al84  
reported a complication rate of 13% in 1164 patients and 31% in 1291 patients, respectively, as 
well as differing major complications. Complication rates vary in VSG patients and range from 
0% to 23.8%66. The most common complications patients encounter with the VSG appear to be 





Journal Articles  
 Of the three articles presented as part of this thesis, one has been published, one is under 
review, and the other is soon to be submitted. The objective of the egg breakfast article was to 
determine whether high protein quality eaten at breakfast affects satiety and food intake at lunch. 
The objective of the two articles on bariatric surgery was to compare the vertical sleeve 
gastrectomy to the Roux-en-Y gastric bypass in terms of weight loss, diabetes resolution, the 
incidence of major and minor complications, and the effect of insurance coverage on weight loss 
and complications.  
 The first article, “Superior Quality of Egg Protein Results in Increased Satiety,” 
compared the effect an egg breakfast containing high quality protein had on satiety and food 
intake compared to a ready-to-eat cereal breakfast matched for energy density and macronutrient 
composition. It has been submitted to the American Journal of Clinical Nutrition. Bayham et al 
found that the egg breakfast reduced cumulative lunchtime intake, decreased acylated ghrelin 
post-breakfast, and increased PYY post-breakfast. The egg breakfast also improved the HOMA 
index in individuals who had greater insulin resistance prior to the study.    
The second article entitled “Early Resolution of Type 2 Diabetes Seen after Roux-en-Y 
Gastric Bypass and Vertical Sleeve Gastrectomy” has been published in Diabetes Technology 
and Therapeutics. Bayham et al found that both operations equally resolved T2D in obese adults, 
but the vertical sleeve gastrectomy had a significantly lower rate of overall complications in 
individuals with T2D. At eight-weeks post-operatively, approximately 79% of RYGB and 83% 
of VSG patients remained off their diabetes medication.  
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 A third article, “Sleeve Gastrectomy Results in Less Weight Loss but Fewer Major 
Complications than the Roux-en-Y Gastric Bypass” will be submitted to the Annals of Family 
Medicine. Bayham et al found that the RYGB resulted in greater weight loss at one and two 





BREAKFAST CONTAINING EGG PROTEINS INDUCES GREATER SATIETY 
COMPARED TO A BREAKFAST WITH LOWER PROTEIN QUALITY 
 
Data from the 2007-2008 National Health and Nutrition Examination Survey (NHANES) 
showed that 68% of adults in the United States (US) are overweight or obese32. Consuming less 
energy than needed for weight maintenance is the cornerstone of weight loss treatment. 
However, long-term compliance following a reduced energy diet is challenging85. Hence, 
additional supportive strategies are needed. Researchers are currently investigating nutritional 
approaches to reduce food intake. Foods differ in their ability to reduce hunger and increase 
satiety21. Breakfast foods with high satiety index scores (SIS) induce a greater feeling of fullness 
compared to those with lower SIS and are also negatively correlated with energy intake at 
lunch85. Therefore, higher SIS breakfasts may help in reducing food intake during a day. 
Eggs, a common breakfast food, have a 50% greater SIS than ready-to-eat (RTE) cereal21. 
An egg breakfast (EB) results in greater feelings of satiety and decreased energy intake at 
lunch22. When habitual EB eaters follow a reduced calorie diet, they reduce their BMI more than 
those who eat an isocaloric bagel breakfast37. 
Incorporating eggs in the diet may supplement weight loss efforts by inducing satiety and 
increasing compliance with a reduced-calorie diet. Eggs are protein-rich and contain high 
concentrations of the branched-chain amino acid (BCAA) leucine44. Leucine plays a role in 
insulin signaling and glucose metabolism44, 86, and it has been shown to decrease food intake and 
body weight48. A mouse model of diet-induced obesity demonstrated that increasing dietary 
leucine reduces inflammation in the adipose tissue and improves glucose tolerance when 
consuming a high-fat diet87. Previous studies that compared the effects of an EB to a bagel 
breakfast did not match them for macronutrient composition, and the EB had a greater amount of 
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protein22, 37. It was unclear if the satiating effect of the EB was due to greater protein quantity or 
the better quality of egg proteins.  
Here we tested the hypothesis that an EB will induce greater satiety than a RTE wheat 
cereal breakfast (CB) with lower protein quality but similar energy density (ED) and 
macronutrient composition. Thus, by matching the protein quantity, we determined if the 
breakfast containing higher quality protein increased satiety and reduce food intake. The 
satiating effects of the breakfasts was assessed at the beginning and end of two, one-week 
periods by hunger and satiety ratings from questionnaires, food intake at lunch, and satiety 
hormone concentrations. Secondarily, we determined changes in indices of glycemic control in 
response to EB and CB consumption.   
Methods 
This study was approved by the institutional review board at Pennington Biomedical 
Research Center. Written informed consent was obtained from the subjects prior to the initiation 
of study procedures.  
Eligibility Criteria  
Individuals were screened over the telephone to determine their eligibility including 
having a BMI > 25 and < 60 kg/m2, being between 18 and 60 years of age, and having lost no 
more than 5% body weight in the three months preceding the study. Those who qualified came to 
the clinic for a screening visit which included a history and physical examination to determine 
eligibility. Individuals with an unstable cardiac condition; major systemic illness; history of drug 
abuse or eating disorder; uncontrolled diabetes or hypothyroidism; familial hyperlipidemia; an 
allergy, sensitivity, or dislike of eggs, soy, or wheat; those attempting to lose weight; or those 




Of the 56 subjects who screened for the study, 20 meet eligibility criteria to enter the 
intervention trial. Subjects were randomized into two groups. One subject withdrew from the 
study and was subsequently replaced. The data collected for the withdrawn subject was 
discarded. Group 1 consumed the EB during the first test week and the CB during the second test 
week, and group 2 consumed the CB during the first test week and the EB during the second test 
week. Subjects completed the study on individual timelines and were not assessed as groups.   
Procedures 
In this randomized, crossover trial, each subject received two diets in random order. Nine 
subjects were randomized to receive the EB, and 11 subjects were randomized to receive the CB 
during the first test week. On day one, subjects reported to the clinic following a 12-hour fast and 
were provided with breakfast at 8:00 AM which they were required to consume completely. The 
EB was similar to the CB in weight (g), caloric content, and macronutrient composition 
(described below and in Table 1). An intravenous line was placed in each subject’s forearm 
before breakfast to collect blood samples until 120 minutes after consuming lunch. Subjects 
remained in the clinic and were given a standardized lunch 180 minutes after they consumed 
breakfast. A questionnaire assessed their satiety and hunger before and after breakfast and lunch 
(described below). To avoid unintentional impact on food intake, the subjects were told the 
purported aim of the study was to determine the effect of breakfast on blood glucose and insulin, 
blood hormones and blood pressure. Subjects came to the clinic for the next six days at 8:00 AM 
in a fasting state to eat the same breakfast consumed on day one. No blood samples were 
collected and lunch was not provided on days 2-6. On day seven, the blood tests and 
questionnaires were repeated and food and water intake were measured following lunch. After 
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the first test week, the subjects underwent a two-week washout period in which they consumed 
their usual pre-study breakfasts. Following the washout period, they returned for the second test 
week, and the cycle was repeated with the opposite breakfast.    
Breakfast and Lunch 
The EB contained two scrambled eggs, 120 ml skim milk, two slices of Holsum® thin 
white bread, 5 g of butter, and 18 g of Smuckers® strawberry jam. The CB contained 1.5 cups of 
Special K® ready-to-eat cereal, 200 ml Silk® original soymilk, one slice of Natural Grain 
“Wheat n’ Fiber”® bread, 13 g of butter, and 10 g of sugar-free strawberry jam. The breakfasts 
were matched for ED and macronutrient composition but differed in the Protein Digestibility 
Corrected Amino Acid Score (PDCAAS)88, leucine content, and glycemic load (Table 1). A 
standardized lunch consisting of lemon sage chicken, wild rice, mixed vegetables, a white dinner 
roll, canned pears, salted butter, 1% milk, and water was provided ad libitum. The amount of 
food and water consumed was covertly weighed both before and after the subject was served.  
Table 1. Energy density, macronutrient composition, and protein score of the breakfasts 
 Egg breakfast Wheat breakfast 
Weight (g) 291 293 
Energy (kcal) 400 398 
Energy density (kcal/g) 1.37 1.36 
Carbohydrate (%) 43.1 44.8 
Fat (%) 36.0 35.4 
Protein (%) 20.2 19.8 
Protein (g) 12.5 13.7 
PDCAAS1 100 42 
Leucine (g) 1.77 0.48 
Glycemic load 24 30.8 










Demographic characteristics – Age, race, and sex were self-reported. Height and 
weight were measured with light clothing and no shoes during the screening visit prior to the 
initiation of study procedures. BMI was calculated as kg/m2 89. Weight was also measured on 
days one and seven of each test week.  
 
Blood chemistry – Blood samples were taken from the subject in a fasting state before 
breakfast was consumed (0 minutes) and were subsequently analyzed to determine fasting serum 
glucose, serum insulin, peptide YY (PYY), acylated ghrelin, and serum leucine. The 
Homeostatic Model Assessment (HOMA) index of insulin resistance was calculated as 
previously described90 using fasting glucose and insulin levels. Blood samples were also taken 
30, 60, 120, and 180 minutes after breakfast and 120 minutes after lunch to repeat the 
assessments of the satiety-related hormones, PYY and acylated ghrelin. To assess serum leucine 
concentrations, blood samples were taken 60 and 300 minutes after breakfast.  
 
Questionnaire – A visual analog scale (VAS) was used to measure hunger and satiety as 
previously described91. It consisted of lines which subjects were asked to mark corresponding to 
their feelings for each question from 0 (not at all) to 100 (most imaginable). The following 
questions were given to the participants using questionnaires presented electronically before and 
after breakfast and lunch: 1) How hungry do you feel at this moment?, 2) How full does your 
stomach feel at this moment?, 3) How strong is your desire to eat at this moment?, 4) How much 





Data were summarized as counts and percents for categorical variables and as means and 
standard deviations for continuous variables. Student’s t-test was employed to assess the 
significance of the difference between EB and CB with respect to (1) change in each of the five 
VAS question during the time increment from 30 minutes to 180 minutes post-breakfast, (2) the 
lunch cumulative energy intake in kcal (day1 + day 7) from fat, carbohydrate, protein and total 
consumption, (3) changes in acylated ghrelin and PYY concentrations, respectively, across time 
(0, 30. 60. 120 and 180 minutes post-breakfast) during day 1 and day 7 of EB and CB breakfasts, 
and (4) change in acylated ghrelin and PYY concentrations, respectively, during the time 
increment between 30 minutes and 180 minutes post-breakfast during day 1 and day 7. Statistical 
analyses were all carried out using SAS® 9.2 (SAS Institute, Inc, Cary , NC 27513). Statistical 
significance was declared for p ≤ 0.05. 
Results 
 A total of 20 subjects completed the study [female (75%), African American (70%), 
mean age 40.7 years, and mean BMI > 30 kg/m2 (Table2)].   
Table 2. Baseline characteristics of participants on day 1 of each breakfast* 
 Group 1 Group 2 
n  9 11 
Male:Female 3:6 2:9 
White:Black 2:7 4:7 
Age, years 41.7±14.4 39.9±14.0 
Weight, kg, EB 100.3±13.9 106.0±20.6 
Weight, kg, CB 99.6±13.5 105.7±19.9 
BMI, kg/m2, EB 35.7±2.8 39.4±9.3 
BMI, kg/m2, CB 35.6±2.9 39.1±9.2 





Total Food and Energy Intake at Lunch   
Subjects had a significantly lower cumulative lunchtime energy intake (kilocalories 
consumed at lunch on days 1 and 7) during the EB week (p=0.05; Figure 1). The difference 
between the two breakfasts in food and energy intake was not significant individually on day 1 or 
day 7. Although the differences were not statistically significant, subjects consumed fewer 



























Figure 1. Cumulative total energy intake (kcal) at lunch (p=0.05) and energy intake from fat, 
carbohydrate, and protein in egg breakfast versus cereal breakfast.  
 
Hunger and Satiety Following Breakfast  
 
 To measure the acute effect of each breakfast, the difference between VAS scores at 30 
and 180 minutes post-breakfast was determined (Table 3). After consuming the EB on day 1, 
subjects felt significantly less hungry before eating lunch than on day 1 of the CB (p=0.002). The 
EB also induced a greater feeling of fullness before eating lunch compared to the CB on day 1 
(p=0.02) and day 7 (p=0.02). The EB resulted in a decreased desire to eat before lunch on day 1 
(p=0.03), and on day 7, subjects felt they could not eat much food at lunchtime (p=0.03). 




the CB increased hunger scores on day 7. The EB did not significantly affect hunger, fullness, 
desire to eat, or satisfaction after lunch was consumed.  
Table 3. Acute effect of egg and cereal breakfasts on change in VAS score from 30 minutes post-
breakfast and 180 minutes post-breakfast between day 1 and day 7 




1 How hungry do you feel at this moment? 0.002* 0.245 
2 How full does your stomach feel at this moment? 0.048* 0.019* 
3 How strong is your desire to eat at this moment? 0.028* 0.173 
4 How much food do you think you could eat at this moment? 0.213 0.029* 
5 How satisfied do you feel at this moment? 0.409 0.077 
*Significance at p < 0.05  
 
Satiety-Related Hormones, Glucose, and Insulin  
High concentrations of acylated ghrelin, the active form of ghrelin, are associated with 
hunger 92 and are typically high before a meal4. Accordingly, acylated ghrelin concentrations 
were greatest before breakfast and decreased 30 minutes post-breakfast. Subsequently, acylated 
ghrelin concentrations increased up to 180 minutes post-breakfast. Compared to the CB, acylated 
ghrelin concentrations were significantly lower 180 minutes following the EB on day one 
(p=0.005; Figure 2).  To measure the acute effect of each breakfast, the difference between 
ghrelin concentrations at 30 and 180 minutes post-breakfast was determined. On day one of the 
EB, acylated ghrelin remained significantly reduced before lunch (p=0.03; Figure 3) but not on 






Figure 2. Acylated ghrelin concentrations on day 1 of the egg and cereal breakfasts were 
different at 180 minutes (p=0.005).   
 
 





































Figure 4. The rise in acylated ghrelin occurring from 30 minutes post-breakfast to 180 minutes 
post-breakfast on days 1 and 7. The EB significantly decreased acylated ghrelin in day 1 
(p=0.03) but not on day 7.   
 
Higher concentrations of PYY are associated with satiety, and following a meal, PYY 
concentrations typically increase4, 93 as they did in this study. PYY concentrations were lowest 
before breakfast but increased post-breakfast and reached their peak after lunch on days 1 and 7 
for both breakfasts. PYY concentrations were significantly greater during the EB week on day 
one 120 minutes and 180 minutes (p=0.006 and p=0.001, respectively; Figure 5) post-breakfast 
and on day seven 180 minutes post-breakfast (p=0.03; Figure 6).  The difference between PYY 
concentrations at 30 and 180 minutes post-breakfast were significantly increased before lunch on 







Figure 5. PYY concentrations on day 1 of the egg and cereal breakfasts were different at 120 























































Figure 7. The change in PYY occurring from 30 minutes post-breakfast to 180 minutes post-
breakfast on day 1 and 7. The EB increased PYY significantly more than the CB on day 1 
(p<0.001) and day 7 (p=0.005).  
 
There were no significant differences in serum glucose, insulin, or leucine concentrations 
between the EB and the CB. However, at the end of the EB week, subjects with leucine 
concentrations in the top 50th percentile before breakfast had a significant improvement in their 
HOMA index for insulin resistance in one week compared to subjects in the bottom 50th 
percentile for leucine (p=0.03). Subjects in the top versus bottom 50th percentiles for leucine had 
an average difference of -0.51±1.51 and 0.63±0.93, respectively, in their HOMA index on day 7 




Because adherence to a low calorie diet can be difficult to maintain over time, dietary 
strategies that decrease hunger and increase satiety may promote compliance and enhance weight 
loss37, 38.  Eggs have a high satiety value21, and thus previous research hypothesized that 
consuming an EB would increase satiety and reduce caloric intake at lunch compared to an 





satiety and significantly lower energy intake during their subsequent meal and for all meals in 
the next 24 hours22, 25. A follow-up study of longer duration compared the effects of the two 
same breakfasts (an EB and a bagel breakfast matched for ED) on weight loss37. Compared to the 
bagel breakfast, the EB significantly increased weight loss and reduced waist circumference in 
individuals following a reduced calorie diet. However, the EB had no significant effect on weight 
loss and waist circumference on individuals not following a reduced calorie diet; therefore, 
including eggs as part of a daily breakfast appears to induce greater results to a weight loss 
regimen. 
  Increased intake of protein, especially those of higher quality, enhances weight loss44, 46, 
47, 49. The satiating effect of eggs may possibly be due to the high quality of egg proteins which 
are rich in leucine, a branched chain amino acid (BCAA) implicated in inducing satiety48, 49, 94. 
Vander Wal et al matched the breakfasts for ED but not macronutrient composition22, 37 so the 
protein quantity as well as the protein quality was slightly higher in the egg breakfasts in these 
studies; therefore, it was unclear if eggs induce satiety due to the quantity or quality of protein. 
To determine the satiating effect of an EB, the two breakfasts compared in this study were nearly 
identical in ED and macronutrient composition and protein quantity but differed in the quality of 
protein. The breakfasts included a primary source of protein from either eggs or wheat which 
have PDCAA scores of 100 and 42, respectively,88 as well as differing leucine content of 8.5% 
and 6.8%, respectively. Because the two breakfasts were nearly identical, the effect of the EB on 
reducing lunchtime food intake was not as pronounced as previously observed22. Nevertheless, 
the higher quality of egg protein appears to significantly affect satiety, lunchtime energy intake, 
and satiety-related hormones.   
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Previous research showed that when dieters consumed an EB daily, they lost significantly 
more weight and display greater dietary restraint and reductions in hunger than bagel breakfast 
eaters37. In contrast, cross-sectional data from NHANES III showed that individuals who 
consumed RTE cereals and other types of wheat-based breakfasts had significantly lower BMIs 
than those who consumed meat and eggs for breakfast40. Meat and egg breakfast eaters were also 
shown to have the highest daily energy intake of all the breakfast groups included in the 
analyses40. While a precise explanation for this discrepancy is unknown, a possible reason may 
be that egg intake is a marker of other dietary indiscretions. For instance, males with the highest 
egg intake reported greater daily energy intake, greater saturated fatty acid intake, and a 5-fold 
greater consumption of bacon than males with the lowest egg intake although their BMIs were 
similar95. Bacon intake correlated with egg intake in males (r=0.35) and females (r=0.21)95.  
Greater weekly egg consumption was positively associated with a less healthful diet, and males 
with greater egg consumption were more likely to consume whole milk, red meat, and bacon95. 
Therefore, the positive association of eggs with BMI may be due to the accompanying foods 
such as bacon that are associated with egg intake. If eggs are consumed without such high fat-
high energy accompaniments, they may influence BMI differently. However, the present study 
was not designed to test this hypothesis.  
Diets high in protein appear to result in greater reductions in weight because protein 
increases satiety and thermogenesis49, 96, reduces loss of lean body mass, promotes body fat loss, 
and improves glycemic control49. Recently, studies showed no particular advantage of dietary 
macronutrient composition, including greater protein intake in long-term weight loss or 
maintenance19. However, this study did not consider protein quality. 
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 Whey, soy, and gluten proteins appear to be equally effective at reducing hunger by 
mediating the endocrine response in the postprandial state97. A breakfast containing 25% whey 
elicited the greatest response in glucagon-like peptide 1 (GLP-1) and insulin94 possibly because 
it has the highest leucine content which increases protein quality47. High protein intake leads to 
greater consumption of the BCAA leucine44, 49. Layman et al46 compared a moderate protein diet 
and a high carbohydrate diet with different amounts of leucine (9.89±0.19 g and 5.39±0.10 g, 
respectively) over a 10-week period. Subjects in the protein group lost more weight and body fat 
but less lean body mass than the carbohydrate group although the differences were not 
significant46. In the present study, although the EB contained three times the amount of leucine 
than the CB (1.77 g and 0.48 g, respectively), no difference was found in serum leucine between 
the EB and CB. The breakfasts may not have contained the amount of leucine needed to change 
serum leucine concentrations in the fed state.  
Leucine intake may influence metabolism in other ways as well. Leucine regulates 
phosphorylation events in the insulin signaling cycle that ultimately leads to the activation of the 
initiation complex and the promotion of protein synthesis49. Leucine also stimulates the pancreas 
to release insulin and modulates the intracellular insulin signals occurring in skeletal muscle and 
adipose tissue49. This suggests that leucine acts as a metabolic regulator, and through its actions 
in insulin and glucose, can preserve lean muscle while reducing body fat. BCAA concentrations, 
including leucine, are elevated in obesity98, and increased levels are correlated with insulin 
resistance99 which suggests that leucine is a biomarker for abnormal carbohydrate metabolism. 
Yet, leucine supplementation improves glycemic control87. While there were no differences in 
the group mean for serum leucine, those in the top 50th percentile for serum leucine showed a 
significant improvement in insulin resistance. Also those in the top 50th percentile for HOMA 
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index (higher insulin resistance) had significantly higher serum leucine and showed an 
improvement in HOMA index. These data suggest that while an EB may influence satiety via 
leucine-independent pathways, EB/leucine may improve insulin resistance.  
No differences were found between the top and bottom percentiles for serum leucine on 
ghrelin or PYY (data not shown). On day 1 of the EB, the subjects’ decreased hunger was 
reflected by the significant decrease in acylated ghrelin concentrations post-breakfast. 
Consuming the EB significantly increased postprandial PYY concentrations up to 3 hours 
following breakfast on both days 1 and 7 which suggests that eggs are more satiating than cereal 
in spite of the fact that they contained the same amount of protein. Thus, protein quality may 
have a greater effect on satiety than protein quantity.  
This study had some limitations. The breakfasts were designed to resemble typical 
breakfasts and inordinate manipulations to the ingredients were avoided. Consequentially, 
although the two breakfasts were closely matched for ED and macronutrient composition, the 
glycemic load for the EB and CB was 24 and 30.8, respectively. Although it is unlikely that 
glycemic load is responsible for the differences in satiety, the contribution of this small 
difference on the favorable effect of the EB on satiety is unknown. Similarly, the role, if any, of 
different types of lipids or other protein sources, including animal proteins, is unknown. GLP-1, 
an anorectic hormone secreted in response to dietary proteins, was not measured. A dose 
response of satiety to egg quantity is also unknown. Future studies should examine whether 
protein quantity and quality work synergistically together to reduce appetite.   
In summary, this study matches the breakfasts for energy density and macronutrient 
composition to compare the effect of protein quality on measures of satiety. Eggs appear to affect 
satiety by decreasing acylated ghrelin and increasing PYY up to four hours following breakfast. 
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These effects were seen despite the closely matched breakfasts. The protein quality does appear 
to affect satiety although this effect may be independent of leucine. Although serum leucine 
concentrations did not correlate with measures of satiety, they do appear to be associated with an 
improvement in glycemic control following just one week of a daily EB. Therefore, due to the 
superior quality of proteins, eggs may provide a useful adjunct in weight management because 
they increase satiety. The satiating role of other foods with higher protein quality should be 
determined. Developing strategies to use foods as appetite suppressants may have considerably 
































EARLY RESOLUTION OF TYPE 2 DIABETES SEEN AFTER ROUX-EN-Y GASTRIC 
BYPASS AND VERTICAL SLEEVE GASTRECTOMY
100
  
 In 2007-2008, approximately 72.5 million adults in the United States were considered 
obese. Data from the 2007-2008 National Health and Nutrition Examination Survey showed an 
overall obesity prevalence of 33.8% and a combined overweight and obesity prevalence of 
68.0%32. Compared with individuals with a normal body mass index (BMI) of 18.5–24.9 kg/m2, 
individuals with a BMI of 30 kg/m2 or more increase their risk of obesity-related diseases101 such 
as cardiovascular disease, hypertension, certain cancers, and type 2 diabetes (T2D)12. 
  More than 8% of the U.S. population is affected by diabetes102. T2D accounts for the 
majority of diagnosed cases of diabetes in adults, whereas type 1 diabetes only accounts for 
5%102.  T2D can be treated with diet, oral hypoglycemics, or insulin therapy. Between 2007 and 
2009, 58% of adults with diabetes reported taking oral hypoglycemic, 12% reported taking 
insulin, and 14% reported taking insulin and oral hypoglycemic103. The average direct medical 
costs of an individual diagnosed with diabetes are more than double those of an individual 
without diabetes103. Typically, diet and other strategies such as behavioral modification and 
exercise result in only limited weight loss, which is usually not maintained72. 
 Bariatric surgery is the most effective tool for substantial weight loss and long-term 
weight maintenance in the obese population and far surpasses nonsurgical obesity treatments104. 
For example, a lifestyle intervention program reported an initial weight loss of 8.6% at 1 year, 
and at 4 years, the individuals maintained a weight loss of 4.7%15 compared with individuals 
who underwent gastric bypass and had an average weight loss of 32% at 1–2 years and 25% at 
10 years27. The laparoscopic technique for Roux-en-Y gastric bypass (RYGB) was introduced in 
100Reprinted by permission of Diabetes Technology and Therapeutics 
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the early 1990s68 and has become the most widely used bariatric operation72. Improvements in 
glycemic control have been seen in RYGB patients postoperatively before substantial weight loss 
has occurred29, 72. The vertical sleeve gastrectomy (VSG), a newer bariatric procedure than the 
RYGB, was originally performed as the first step in a two-step procedure leading to either a 
RYGB or a biliopancreatic diversion with a duodenal switch in superobese patients (see 
Appendix B)12, 13, 70, 104, 105. However, several studies have indicated that the laparoscopic VSG 
can act as a stand-alone procedure and be as effective as the RYGB in initiating weight loss and 
resolving T2D70, 72, 104. The VSG has provided promising results as a primary operation15, 
although nationwide it accounts for only 7.6% of bariatric operations106.   
Several studies have compared the effect of the RYGB to the VSG in diabetes patients; 
however, these had a maximum of 91 subjects and focused on follow-up data at 1 or more 
years71, 73, 74, 104. One of the most remarkable features of the RYGB is rapid diabetes resolution 
before significant weight loss29, 68. Only one of the studies comparing glucose metabolism 
following RYGB and VSG in patients concentrated on the early postoperative period of 1–3 
months; the study concluded that both operations led to improvements in glucose homeostasis, 
but it only had 13 RYGB patients and 14 VSG patients72. The current study compared a much 
larger group of diabetes subjects taking medications who were operated on by the same two 
surgeons with over 120 patients in both surgical groups. Because there has been a focus on the 
early resolution of diabetes prior to significant weight loss with both the RYGB and VSG, the 
goal of this retrospective study was to compare the respective efficacy of the two surgeries in 





Between 2002 and 2010, obese patients with T2D (n = 262) on hypoglycemic medication 
underwent either the RYGB (n = 123) or the VSG (n = 139). All data were obtained from the 
surgeons’ office and recorded retrospectively. The surgeon provided a timeline that requested the 
patient return for follow-up visits at 2 weeks, 2 months, 6 months, and annually for 5 years; 
however, according to the surgeons, many patients discontinue follow-up at 2 months if they do 
not develop any complications. 
Diabetes Medication  
All preoperative medications were recorded for each patient. Follow-up data were used to 
determine if the patient resumed, discontinued, or changed medications postoperatively. T2D 
resolution was defined as no longer requiring diabetes medication following surgery. Because 
routine fasting blood glucose measurements were not taken, improvement in T2D control was 
defined as a reduction in the number of diabetes medications taken postoperatively. Combination 
therapy was defined as taking both insulin and an oral hypoglycemic medication. 
Complications  
Every complication occurring during or following surgery for each patient was recorded. 
The total number of complications was determined for the hospital stay and upon discharge for 
both operations. RYGB patients had longer hospitalizations with more records of temperatures 
and vital signs, routine urinalysis, and complete blood count, notation of cholelithiasis on 
operative reports, and routine chest X-rays that were not routinely performed in VSG patients. 
Thus, atelectasis, anemia, elevated blood pressure, fever, hematuria, and cholelithiasis were 
removed from the analysis because they were more likely to be recorded as complications in the 
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RYGB group compared with the VSG group. The remaining complications were separated into 
major and minor categories based on the judgment of the surgeons. Once these adjustments were 
made, the incidence of overall major and minor complications was determined. Table 4 lists all 
major and minor complications included in the analyses. 
Table 4. Complete List of Complications for Both Operations Used in the Data 
Analyses 
Major Complications Minor Complications 
• Gastrointestinal leak 
• Anastomotic stricture 
• Small bowel obstruction 
• Hernia 
• Small bowel incarceration 
• Gastrointestinal bleed 
• Hypotension 
• Cardiac ectopy  




• Pouch laceration 
• Azotemia 
• Heart failure 
• CO2 narcosis 
• Ventricular bigeminy 
• Pulmonary venous congestion 
• Septicemia 
• Shock 
• Anastomotic ulcer 
• Mesenteric venous thrombosis 
• Hematemesis 
• Peptic or Perforated ulcer 
• Deep vein thrombosis 
• Pulmonary embolus 
• Adhesions 
• Fistula 
• Guillain-Barre syndrome 
• Pancreatitis 
• Small bowel intussusception 
• Necrotic small bowel 
• Perforation 
• Gout 






• Anastomotic edema 
• Elevated hepatic transaminases 
• Gastroparesis 
• Abdominal wall abscess 
• Malnutrition 
• Gastritis 
• Dumping syndrome 
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• Omental torsion 
• Blind pouch syndrome 
• Death 
 
Statistical Analysis  
All data were analyzed using a χ2 distribution. A P value of < 0.05 was considered 
statistically significant. 
Results  
Although patients were given a schedule to follow, many were noncompliant, and 
therefore there was great variability in the timing of follow-up visits. 
Demographics  
Age, weight, and BMI are given as mean ± SD values (Table 5). Race was not recorded 
for 49 RYGB patients and 30 VSG patients. There were no significant differences in the patient 
demographics when comparing the two surgical groups. 
Table 5. Pre-operative Characteristics of Study Population According to 
Operation 




n 123 139 
Age, years  46.8±9.5 (18-65) 50.5±10.3 (18-73) 
Weight, kg  137.0±26.5 (95.9-225.0) 131.3±29.0 (68.2-235.0) 
BMI, kg/m2  48.7±8.1 (37-69.6) 45.8±9.0 (30.9-72.1) 
Sex (% Female) 78.0 66.9 
Race (%) 
• White  
• Black  
• Hispanic  











Data are mean ± SD values (range) as indicated. 
(Table 4 continued) 
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BMI, body mass index. 
 
Change in Diabetes Medication Usage  
Upon discharge, 95 of the 123 (77.2%) RYGB and 107 of the 139 (77.0%) VSG patients 
had been taken off their diabetes medication. Seventeen of the 26 (65.4%) RYGB patients and 19 
of the 32 (59.4%) VSG patients who remained on diabetes medication up to 8 weeks 
postoperatively showed improvement in their diabetes control by reducing the number of 
medications taken and were not significantly different. Two RYGB patients who were not taking 
diabetes medication preoperatively began taking them postoperatively. Patients who reported 
taking medications postoperatively either remained on the same therapy as preoperatively or 
switched to another type of therapy (Table 6). 
Table 6. Patients Reporting Diabetic Medication Use Post-Operatively 




n 28a 32b 
No Changec 15 (53.6) 21 (67.7) 
Combination Therapy 
 Insulin 
5 (17.8) 5 (16.1) 
Combination Therapy 
 Oral Agent  
1 (3.6) 4 (13.0) 
Oral Agent  Insulin 7 (25.0) 1 (3.2) 
Data are number of patients (%). 
P < 0.05 versus bypass versus sleeve for all rows (one-tailed t test). 
aTwo patients who were not on pre-operative medications began taking them post-
operatively. They are reported as no change.  
bOne patient reported taking medication pre- and post-operatively but the chart 
did not specify what kind of therapy; therefore, this patient’s data is unreported 
and the percentages were found using n=31.    
cIndicates patient remained on same therapy (oral, insulin, or combination) post-
operatively.  
 
Table 5 continued 
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Eight weeks postoperatively, follow-up data were available for 38 RYGB patients and 71 
VSG patients. Approximately 79% (n = 30) of RYGB patients and 83% (n = 59) of VSG patients 
remained off diabetes medication. 
Incidence of Complications  
The overall incidence of major and minor complications was 24.8% and 22.8%, 
respectively, for RYGB patients and 3.6% and 6%, respectively, for VSG patients (P < 0.001). 
The incidence of complications both perioperatively and after discharge is shown in Table 7.  
Table 7. Number of Diabetic Individuals Who Experienced a Complication Due to 
Surgery 
 Surgery [n (%)] 

















1 (0.6) 5 (3.0) 1 (0.6) 9 (5.4) 
abcP < 0.001 for comparison of procedures. 
dP < 0.025 for comparison of procedures. 
 
Discussion  
Although diabetes medications help control blood glucose levels, they may not prevent 
the progression of the disease process, which leads to microvascular complications including 
retinopathy, nephropathy, and neuropathy. T2D may also lead to cardiovascular disease, which, 
in the United States, accounts for the death of 70% of individuals with T2D68. Bariatric surgery 
appears to be the best method to prevent the occurrence and progression of T2D29, 68. 
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Although this study and the study by Peterli et al72 are the only studies to focus on the 
early response of T2D to both RYGB and VSG, other studies have evaluated the later response 
of T2D to these operations71, 73, 74, 104. Similar to this study’s results, some of these other studies 
found that VSG has similar efficacy as that reported for T2D remission with RYGB70, 71. One 
found that both RYGB and VSG had a resolution rate of approximately 85% in 91 patients at 12 
months postoperatively70, and another showed no significant differences in T2DM between the 
two surgeries at 1 and 2 years postoperatively in 90 patients71. Both surgeries appeared to result 
in early, dramatic improvements in glycemic control that was maintained postoperatively72. 
However, some studies still suggest that RYGB may lead to better T2DM resolution, possibly 
because of the exclusion of the proximal small intestines from the stream of undigested chyme73. 
For example, one study that compared T2D remission for both operations showed almost a 
twofold higher remission in RYGB patients compared with VSG patients73. In contrast, another 
study reported greater diabetes resolution in VSG patients compared with RYGB patients74. 
Approximately 76% of VSG patients discontinued their diabetes pharmacologic treatment 
compared with only 60% of RYGB patients74. Similarly, other studies report discontinuation of 
diabetes medication in the majority of VSG patients13, 70. 
A high preoperative BMI, a previous bariatric operation, and T2D have been shown to be 
positive predictors for the occurrence of surgical complications105. Several case series have 
reported complication rates less than 10% in VSG patients12, 105, 106. Similarly, our study showed 
an overall complication rate of 9.6% in diabetes patients undergoing VSG. In contrast, RYGB 
patients appear to be more at risk for postoperative complications. Schauer et al 68 found an 
overall major complication rate of 13.6% and minor complication rate of 24.9% in 191 diabetes 
patients undergoing RYGB. The current study showed a higher incidence of major complications 
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in the RYGB group (24.7%), but the minor complication rate (22.8%) was similar to the results 
of Schauer et al68. Major complications commonly reported include gastrointestinal leaks15, 29, 
small bowel obstructions13, 68, and deep vein thromboses68. Minor complications commonly 
reported include wound infection13, 29, 68, nausea and vomiting68, and ulcers68. The only death 
reported in this review was a bypass patient with T2D who died less than 6 weeks 
postoperatively because of a pulmonary embolism. Similarly, other studies have suggested low 
mortality rates: Basso et al13 reported only two deaths in 300 cases, and Gan et al107 reported no 
deaths in 378 cases. In spite of the risk of complications, bariatric surgery is associated with 
decreased overall mortality compared with findings among obese individuals seeking 
conventional treatment27. 
Limitations of this study include missing demographic data, which may skew the means 
for both operations. Another limitation is the lack of laboratory data showing pre- and 
postoperative blood glucose and hemoglobin A1c levels to confirm improvement in blood 
glucose control. Follow-up was marginal so long-term maintenance could not be determined. 
Long-term complications such as osteoporosis and vitamin deficiencies are typically handled by 
the patient’s primary care physician. Because these charts could not be accessed, long-term 
complications were not recorded so that their prevalence would not be underestimated. 
Conclusions 
Bariatric surgery appears to be an effective treatment for diabetes. Both the RYGB and 
VSG appear to give similar early resolution to diabetes prior to significant weight loss in more 
than half of the operated patients. Many individuals who were unable to discontinue their 
diabetes medications were able to reduce the number of medications. The risk of complications 
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also appears to be relatively low, especially in VSG patients. This review supports prior evidence 
that bariatric surgery is a very successful treatment for obese individuals with diabetes seeking 
optimal glycemic control. Although our study has limited long-term follow-up, we focused on 
the question of early diabetes resolution as measured by the ability to stop hypoglycemic 
medication in a large group of community-operated patients. RYGB and VSG seem to have a 
similar positive effect on the early resolution of diabetes; however, the rate of complications was 
less with the VSG. Therefore, the VSG should be considered as a viable option for individuals 















SLEEVE GASTRECTOMY RESULTS IN LESS WEIGHT LOSS BUT FEWER MAJOR 
COMPLICATIONS THAN THE ROUX-EN-Y GASTRIC BYPASS 
 
 Data from the 2007-2008 National Health and Nutrition Examination Survey (NHANES) 
was used to show that 33.8% of adults in the United States (US) are obese32. Bariatric surgery is 
the most effective therapy for morbid obesity8, and its use has increased exponentially over the 
past decade from approximately 13,400 surgeries in 1998108 to approximately 220,000 surgeries 
in 2008109. However, only 1% of clinically eligible individuals are using bariatric surgery as a 
treatment option for morbid obesity109. Data from the Bariatric Outcomes Longitudinal Database 
(BOLD) demonstrated that the majority of individuals seeking bariatric surgery are adults 26-55 
years of age (71.2%), females (78.8%), and white (78.1%), and more than half of these 
individuals undergo the gastric bypass operation57. A newer bariatric operation, the vertical 
sleeve gastrectomy (VSG), has emerged as a one-step procedure from the first step in creating 
the biliopancreatic diversion with a duodenal switch13, 54 for super obese patients. Although the 
VSG accounts for less than 5% of all bariatric procedures performed in the US57, 59, it appears to 
be safe, results in adequate weight loss, and is gaining recognition as a suitable treatment for the 
morbidly obese patient.  
 Bariatric surgery has been shown to result in more significant long-term weight loss 
compared to non-operative methods such as diet and exercise15, 27, 28, 56, 67. The average body 
mass index (BMI) for individuals electing to have bariatric surgery is greater than 40 kg/m2 61, 62, 
76. Bariatric surgery results in substantial weight loss and improvement or resolution of co-
morbid conditions31, 76 but can be accompanied by complications. The incidence of 
complications associated with the Roux-en-Y gastric bypass (RYGB) and the VSG is low3, 53 
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which may be due in part to a growth in the experience of surgeons and the introduction of 
laparoscopic techniques8, 28, 110.  
Many of the bariatric surgical series have been reported from academic centers14, 57, 59, 
but as the number of bariatric surgeries performed annually continues to rise, community 
surgeons are performing the operations more frequently. The community surgeon meets with the 
patient pre-operatively and for several weeks post-operatively. If a patient does not encounter an 
early serious surgery-related complication, the patient may seek follow-up with their family 
physician after the first six weeks of the post-operative period for continued care. Although there 
are guidelines for the pre- and post-operative care of bariatric patients111, 112, family physicians 
should also understand the bariatric operations used, their potential for weight loss, improvement 
of co-morbid conditions, and the associated surgical complications occurring in the initial post-
operative period. The objective of this report is to compare the weight loss and early surgical 
complications in more than 1600 patients who underwent either the RYGB or the VSG in a 
private community surgical practice.   
Methods 
This study was exempted by the institutional review board at Pennington Biomedical 
Research Center.  
Subjects 
 We conducted a retrospective chart review of 835 RYGB patients and 766 VSG patients 
who underwent their operation between 2002 and 2010 by two surgeons in a private community 
surgical practice. All of the patients met the eligibility criteria for bariatric surgery as defined by 
the National Institutes of Health35. The patients were divided into either insured or self-pay 
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categories based upon information provided in the chart. We hypothesized that self-pay patients 
would lose more weight based on their greater personal financial investment in the procedure and 
maintain better long-term weight loss than individuals who had insurance reimbursement. 
Because some demographic data were missing, the missing data were subtracted from the group 
total and the new totals were used to compute percentages for age, sex, race, and insurance 
coverage.     
Weight Loss 
 Each patient’s weight on the day before or the day of surgery was documented as the 
patient’s baseline weight. Post-operative weights were recorded at the weekly time points on 
which they were obtained for up to two years. The patients’ weights between 26-52 weeks and 
78-104 weeks were compared to their baseline weight to determine the percentage of total body 
weight lost at one and two years. The weight loss in insured and self-pay patients in both surgical 
groups was also compared.  
Complications 
 Any event occurring during surgery or within the first six weeks post-operatively was 
recorded for every patient for both operations. The recorded complications were divided into 
minor and major categories  in consultation with the operating surgeons  following the guidelines 
of the American Society for Metabolic and Bariatric Surgery3. The surgical complications in 





Statistical Analyses  
 A Student’s t-Test was used to determine differences in normally distributed data. The χ2 
distribution was used to determine differences in categorical data. Significance was defined as α 
< 0.05.  
Results  
Age, gender, race, pre-operative weight, pre-operative BMI, and insurance coverage were 
recorded if available in the patient’s chart (Table 8). On average, VSG patients were 
approximately three years older than RYGB patients. Significantly more white individuals 
underwent surgery than blacks (p=0.025) or Hispanics and other ethnicities (p=0.015). 
Significantly more females underwent surgery than males (p=0.004). Baseline weight and 
baseline BMI were different between the two surgical groups (p<0.001).  
Table 8. Pre-Operative Demographic Characteristics of Patients in Each Surgical Group  
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Age is presented as the mean ± standard deviation (range).   
Weight and BMI are presented as mea n± standard deviation.  
 
Weight Loss 
There was a significant difference in the percentage of initial weight lost between the 
RYGB and VSG surgical groups at one (p<0.001) and two years (p<0.001; Figure 8).  At one 
year, RYGB patients (n=158) lost 36.4% and VSG patients (n=242) lost 29% of their baseline 
body weight. At two years, RYGB patients (n=39) lost 42.7% whereas VSG patients (n=135) 
lost 30.3% of their baseline body weight.  
 
Figure 8. The Roux-en-Y gastric bypass results in greater weight loss at one and two years 
(p<0.001 for both).  
 
There were no differences in weight loss between self-pay and insured RYGB and VSG 
patients (Table 9). Self-pay patients in both surgical groups continued to lose weight up to two 



































Table 8 continued 
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this difference was not statistically significant. RYGB patients with insurance coverage 
continued to lose weight up to two years, but insured VSG patients re-gained almost 8% of their 
weight at two years.  
Table 9. Percentage of Weight Loss between the Roux-en-Y Gastric Bypass and the Vertical 
Sleeve Gastrectomy at 1 and 2 Years Based upon Payment Methoda 
 Roux-en-Y Gastric Bypass Vertical Sleeve Gastrectomy 
 1 year 2 years 1 year 2 years 
Insurance 36.7±9.7 45.6±23.4 27.7±10.5 19.8±29.0 
Self-pay 34.0±8.0 41.9±27.4 27.0±9.3 28.7±23.5 
aMean ± standard deviation 
 
Complications  
RYGB patients experienced a significantly higher incidence of complications than VSG 
patients (p<0.001). During the peri-operative period in the hospital, 20.4% (n=170) of RYGB 
patients and 1.0% (n=8) of VSG patients experienced a complication.  In the first six weeks post-
operatively, 15.4% (n=129) of RYGB patients and 4.2% (n=32) of VSG patients experienced a 
complication. RYGB patients experienced a greater number of the following major 
complications than VSG patients:  stricture (p<0.001), gastrointestinal bleed (p<0.001), small 
bowel obstruction (p<0.025), and cardiopulmonary complications (p<0.001).  The incidence of 
gastrointestinal leaks and thromboembolic complications was not different in the RYGB and 
VSG operations (Table 10). There were no differences in surgical complications between insured 




Table 10. Incidence of Major Complications among Total Population* 
 Roux-en-Y Gastric Bypass Vertical Sleeve Gastrectomy 
Stricture1 26 (3.1) 2 (0.3) 
Gastrointestinal Bleed1 25 (3.0) 1 (0.1) 
Gastrointestinal Leak 4 (0.5) 0 (0) 
Small Bowel Obstruction2 9 (1.1) 0 (0) 
Cardiopulmonary1 19 (2.3) 2 (0.3) 






Bariatric surgery is the most effective treatment for morbid obesity because it 
significantly reduces body weight, sustains weight loss, and improves co-morbidities associated 
with obesity to a greater extent than non-surgical treatments8, 113, 114. Individuals typically seek a 
weight loss operation when other treatment options such as diet, exercise, and behavioral 
modifications fail to produce substantial or durable weight loss8, 114. Obesity decreases life 
expectancy28, but undergoing bariatric surgery can decrease the risk of mortality in the morbidly 
obese by 35% compared to non-operated controls14, 15. This increase in life expectancy appears to 
be due to the improvement or resolution in obesity-related co-morbidities such as type 2 
diabetes, certain cancers, and heart disease61, 115.  
 Lifestyle modification programs report only modest weight loss usually followed by 
weight regain27, and pharmacologic therapies such as orlistat and phentermine produce a weight 
loss of only 2.9-3.6 kilograms after one year27, 50, 116. The RYGB has been reported to result in 
maximum total body weight loss of 32% at one to two years15. Surgical journals express weight 
loss as a percent of excess weight loss [(weight loss/excess weight)*100 where excess weight is 
baseline weight minus ideal weight as defined by the 1983 Metropolitan Life Insurance Tables 
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for a medium frame]. The RYGB has been shown to result in excess weight losses of 70% at two 
years, 58% at 5 years, and 55% after ten years29. Our retrospective review showed greater total 
body weight loss at one and two years for RYGB patients, and the VSG patients in our study lost 
an amount of weight similar to that previously reported for the RYGB15, 117. Mean percent excess 
weight loss reported for VSG patients ranges from 49-62% at one year62, 63, 65 and up to 68% at 
two years64. The VSG results in considerable excess weight loss at one year in obese patients 
with lower BMIs54 and has been favored by surgeons in high-risk populations118. Although some 
weight regain occurs, the excess weight loss exceeds the results of non-surgical treatment 
options.  
This study showed a drastic gap in insurance coverage between the RYGB and VSG 
surgical groups. Because the RYGB is a more established operation, the percentage of 
individuals undergoing the RYGB covered by insurance was much greater than the newer VSG. 
A review of over 66,000 bariatric surgeries between 2005 and 2007 in the US found that ~87% 
of individuals had private or some other form of insurance whereas almost 6% were uninsured59; 
however, the effect of insurance coverage on weight loss was not discussed. We hypothesized 
that individuals who paid for their operation would lose more weight than individuals who were 
covered by insurance. Although there was no statistical difference in weight loss between self-
pay and insured patients, self-pay VSG patients had numerically greater weight loss than insured 
VSG patients at two years.  There was no weight loss advantage to self-pay patients in the 
RYGB group.  
Common minor complications identified by the American Society for Metabolic and 
Bariatric Surgery (ASMBS) include atelectasis, dehydration, diarrhea, dumping syndrome, 
esophageal reflux, pneumonia, nausea and vomiting, and infection. Common major 
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complications include cardiopulmonary issues such as cardiac arrest, deep venous thrombosis, 
pulmonary embolism and respiratory arrest or failure, gastrointestinal (GI) bleeds or leaks, small 
bowel obstruction, anastomotic stricture, ulcer at the anastomosis or in the GI tract, and wound 
dehiscence or infection.  
The most common of these complications experienced by patients appears to be 
dependent on the type of surgery and their surgeon’s experience. Similar to our study, 
Carrodeguas et al84 found anastomotic strictures to be the most commonly experienced 
complication (7.3%) among the 1300 RYGB patients. Gastrointestinal bleeds and 
cardiopulmonary-related problems were the other top reported complications among RYGB 
patients in our study. Less than 5% of VSG patients from our study experienced a complication 
in the first six weeks of the post-operative period. The top three reported complications in the 
VSG group were thromboembolic-related, strictures, and cardiopulmonary-related adverse 
events. In contrast, other studies report slightly higher overall VSG complication rates ranging 
between 5-9% with the most commonly reported complications being GI bleeds and GI leaks12, 
13. The success of the surgeons in reducing gastrointestinal leaks in our study may be attributable 
to the operative technique they utilized and have previously published53.   
Studies have shown low overall mortality rates following bariatric surgery ranging from 
0.1% to 1.5%57, 59, 77. Thirty-day mortality rates appeared to be less than 0.2% for all types of 
bariatric surgery and less than 2% specifically for RYGB. The mortality rate for VSG appears to 
be less than 1%12, 13, 79. According to data of over 66,000 surgeries from ASMBS Centers of 
Excellence, the three predominant causes of mortality were pulmonary emboli, cardiac 
complications, and sepsis/infection59. In our study, two deaths occurred during the initial post-
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operative period: one RYGB patient and one VSG patient each died due to a pulmonary 
embolism.  
The limitation of this study was the short duration of follow-up for the majority of 
patients although the surgeons encourage their patients to adhere to a five-year follow-up 
regimen. It appeared that the long-term follow up care after the initial six-week post-operative 
period was performed by the patients’ family physician. Our study is one of the first comparative 
studies with a large number of sleeve gastrectomy patients. The weight loss reported for VSG 
patients in this study is similar to weight loss reported in previous RYGB studies. Therefore, we 
feel that the VSG is a viable option for obese patients seeking weight loss surgery. The incidence 
of complications was much lower in the VSG surgical group, a finding which will hopefully 
encourage a greater acceptance of bariatric surgery by insurance providers and family 
physicians. The low mortality rates following bariatric surgery reported in our study and several 
other studies are evidence that the operations are growing safer as the techniques become more 
standardized. Overall, bariatric surgical risks appear to be low.  Therefore, when conventional 
treatments for weight loss have failed, obese individuals and their family physicians should 
consider bariatric surgery in their weight loss discussions. Now that family physicians are 
becoming more involved in the pre- and post-operative care of bariatric surgery patients, the 
patients may seek advice from them on surgery selection. Additionally, the VSG should be 
regarded as an alternative to the RYGB because it is becoming more widely used throughout the 







 These three studies have evaluated two of the most commonly used treatment alternatives 
to combat obesity. An egg breakfast can decrease hunger and enhance feelings of fullness 
because eggs contain high quality protein. Because consuming an egg breakfast daily increases 
satiety, individuals following a diet should be encouraged to try this strategy to further promote 
weight loss. If weight loss cannot be achieved through diet, exercise, or behavioral modification, 
bariatric surgery is the most effective treatment for obesity. Two bariatric operations, the RYGB 
and the VSG, both improved or resolved T2D in the early post-operative period in a large 
percentage of patients. The surgeries also resulted in significant weight loss at one and two years. 
Complication rates and mortality appear to be low, especially in VSG patients. Therefore, 
bariatric surgery appears to be a safe, effective tool for weight loss and co-morbidity 
improvement or resolution.  
 One randomized trial examining 811 overweight and obese adults following different, 
calorie-restricted diets up to two years showed that no specific macronutrient composition diet 
led to greater weight loss than another19. The different diets led to similar results because they all 
restricted daily caloric consumption19. However, maintaining a long-term, calorie-restricted diet 
can be difficult so dietary strategies that increase satiety may be effective tools. Previous 
research has shown that a breakfast containing protein decreases hunger23 and increases satiety45, 
but no study has investigated the effect of protein quantity compared to protein quality. Eggs 
contain the BCAA leucine which increases the protein quality. Despite the fact that the EB was 
matched with an isocaloric RTE CB for ED and macronutrient composition, the EB led to 
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significantly lower concentrations of acylated ghrelin and higher concentrations of PYY than the 
CB and these effects appear to be independent of leucine.  
 However, individuals with higher serum leucine concentrations displayed greater 
improvements in their HOMA index for insulin resistance in just one week. Thus, individuals 
with insulin resistance may benefit from consuming a daily EB because it may potentially 
prevent the progression to T2D. Individuals who have already been diagnosed with T2D may 
gain the greatest control through bariatric surgery. Patients who underwent the RYGB returned 
to normal blood glucose levels before significant weight loss occurred29. More than 75% of 
RYGB and VSG patients were able to eliminate the need for medication in the early post-
operative period. More than half were able to remain off medication at eight weeks post-
operatively. Thus, these studies are informative in regard to the prevention and treatment of T2D.     
 Neither breakfast resulted in a decrease in energy intake or body weight at the end of the 
test week; however, the breakfast study was short in duration, and weight loss is likely if 
individuals consume eggs for breakfast for a longer duration of time in addition to energy 
restriction37. In contrast, bariatric surgery has been shown to produce significant weight loss that 
can be sustained over time29, 66. The RYGB produced significantly greater weight loss than the 
VSG at one and two years, but all patients continued to lose weight up to two years post-
operatively regardless of the type of operation. Self-pay patients who underwent either operation 
did not lose more weight than insured patients. Although the RYGB resulted in greater weight 
loss, it also led to more overall and major complications than the VSG. Mortality from either 
operation was less than 0.3%.  
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 These studies had several limitations. In the breakfast study, the EB and CB were not 
matched for other factors that influence satiety such as glycemic index, and the contribution of 
such factors to the results cannot be accounted for in the study. Also, GLP-1, an anorectic 
hormone known to increase satiety following a meal, was not measured. The short duration of 
the study precluded the evaluation of the effect of protein quality on weight loss. The marginal 
long-term follow-up was the biggest limitation of the bariatric surgery retrospective chart review, 
but it reflects the reality of a community surgical practice where many patients discontinue care 
with the surgeon if no major complications arise during the early post-operative period. A greater 
number of individuals with follow-up two or more years post-operatively would more accurately 
illustrate the differences between the RYGB and the VSG. The charts also lacked laboratory data 
that would have provided information on glucose and insulin concentrations, HbA1c levels, lipid 
profiles, blood pressures, and vitamin levels in bariatric patients. Because the study examining 
diabetes improvement and resolution lacked these data, diabetes improvement and resolution had 
was defined as a decrease in the number of hypoglycemic medications taken or the 
discontinuation of medications taken, respectively.  
 Future studies pertaining to breakfast consumption should continue to examine the effects 
of high protein quality on hunger, satiety, and energy intake. The roles of leucine and GLP-1 
remain to be examined. Future studies that focus on the effects of bariatric surgery on type 2 
diabetes should try to explore the mechanisms involved in the quick improvement seen in blood 
glucose levels before significant weight loss occurs. The low prevalence of gastrointestinal leaks 




 This thesis contributes to the peer-reviewed literature. First, it demonstrates the role of 
protein quality in controlling hunger and satiety. Secondly, the bariatric surgery studies are two 
of the first studies comparing a large group of RYGB and VSG patients and their difference in 
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APPENDIX B  
SLEEVE GASTRECTOMY SURGICAL TECHNIQUE 
 The sleeve gastrectomy has been recognized as a viable bariatric surgical procedure in 
selected patients since 2007.119 The sleeve gastrectomy is commonly performed via the 
laparoscopic approach. The greater curvature of the stomach is devascularized, and a sizing 
dilator is inserted within the stomach and positioned medially along the lesser curve. Using the 
dilator as a “template,” the antrum, body, and fundus of the stomach lateral to the dilator is 
resected and removed, leaving a tubular stomach of approximately 90–120 mL in volume. This 
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